Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder

Mammalian Target of Rapamycin (mTOR) Regulates Cellular Proliferation and Tumor Growth in Urothelial Carcinoma

(2010) Donna E. Hansel et al.   AMERICAN JOURNAL OF PATHOLOGY

Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway

(2010) Christina Barbara Ching et al.   LABORATORY INVESTIGATION

Activation of the PI3K/AKT Pathway Induces Urothelial Carcinoma of the Renal Pelvis: Identification in Human Tumors and Confirmation in Animal Models

(2009) C.-N. Qian et al.   CANCER RESEARCH

Inactivation of p53 and Pten promotes invasive bladder cancer

(2009) A. M. Puzio-Kuter et al.   GENES & DEVELOPMENT

The role of mTOR in the management of solid tumors: An overview

(2008) Alex S. Strimpakos et al.   CANCER TREATMENT REVIEWS

Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies: Figure 1.

(2008) Jorge A. Garcia et al.   MOLECULAR CANCER THERAPEUTICS

Analysis of the expression of biomarkers in urinary bladder cancer using a tissue microarray

(2008) Loleta D. Harris et al.   MOLECULAR CARCINOGENESIS

Phospholipase D1 is an effector of Rheb in the mTOR pathway

(2008) Y. Sun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA